SCHEMBL21848002

SCHEMBL21848002

O=C(O)CCC#CC(=O)OC(=O)C#CCCC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
EGLN1 Q9GZT9 2/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
MAPK1 P28482 1/20 0.35
SLC13A3 Q8WWT9 1/20 0.35
OR51E2 Q9H255 1/20 0.35
EPHX2 P34913 1/20 0.34
PTPN7 P35236 5/20 0.33
HMGCR P04035 3/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
MAPT P10636 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TSHR P16473 2/20 0.32
NFKB1 P19838 1/20 0.32
PMP22 Q01453 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10163042 0.79 EPHX2 (0.38) LMNAEGLN1EPHX2PTPN7HMGCR
SCHEMBL2396 0.77 LMNA (0.42) LMNAEGLN1ALKBH5SUCNR1MAPK1
SCHEMBL4972079 0.76 LMNA (0.53) LMNAEGLN1ALKBH5SUCNR1MAPK1
SCHEMBL9823904 0.75 LMNA (0.40) LMNAEGLN1ALKBH5SUCNR1MAPK1
SCHEMBL21847997 0.75 FFAR3 (0.32) FFAR3
SCHEMBL9677076 0.73 ALDH1A1 (0.35) LMNAPTPN7HMGCRHSD17B10TDP1
SCHEMBL416253 0.71 HMGCR (0.52) LMNAEGLN1ALKBH5SUCNR1EPHX2
SCHEMBL8847239 0.70 EPHX2 (0.38) LMNAEPHX2PTPN7HMGCRSLC22A6
SCHEMBL4241662 0.69 HMGCR (0.50) LMNAEGLN1ALKBH5SUCNR1EPHX2
SCHEMBL8847421 0.68 FFAR1 (0.39) LMNAEGLN1ALKBH5SUCNR1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4391139-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM ION SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2024-06-26 EP disclosed
US-12015121-B2 Electrolyte, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-06-18 US disclosed
US-12002926-B2 Electrolyte, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-06-04 US disclosed
US-11996522-B2 Electrolyte, electrochemical device, lithium-ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-05-28 US disclosed
US-20240154170-A1 NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE MITSUBISHI CHEMICAL CORPORATION (JP) 2024-05-09 US disclosed
US-20240145780-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2024-05-02 US disclosed
US-11945776-B2 Electrolyte, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-04-02 US disclosed
US-11916195-B2 Electrolyte solution, electrochemical device, lithium ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2024-02-27 US disclosed
EP-4293007-A1 COMPOUND, COMPOSITION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE Daikin Industries, Ltd. (JP) 2023-12-20 EP disclosed
US-20230387465-A1 COMPOUND, COMPOSITION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2023-11-30 US disclosed
US-20200274200-A1 ELECTROLYTE FOR LITHIUM ION SECONDARY BATTERY, LITHIUM ION SECONDARY BATTERY, AND MODULE TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2020-08-27 US disclosed
US-20200274199-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ENERGY DEVICE USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2020-08-27 US disclosed
EP-3694041-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY CELL, AND MODULE Daikin Industries, Ltd. (JP) 2020-08-12 EP disclosed
EP-3691016-A1 ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, AND LITHIUM ION SECONDARY BATTERY AND MODULE Daikin Industries, Ltd. (JP) 2020-08-05 EP disclosed
US-20200243911-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD (JP) 2020-07-30 US disclosed
EP-3686983-A1 NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE Mitsubishi Chemical Corporation (JP) 2020-07-29 EP disclosed
US-20200220222-A1 NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE MITSUBISHI CHEMICAL CORPORATION (JP) 2020-07-09 US disclosed
US-20200203769-A1 ELECTROLYTE FOR LITHIUM ION SECONDARY BATTERY, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2020-06-25 US disclosed
EP-3651255-A1 ELECTROLYTE FOR LITHIUM ION SECONDARY BATTERY, LITHIUM ION SECONDARY BATTERY, AND MODULE Daikin Industries, Ltd. (JP) 2020-05-13 EP disclosed
EP-3641043-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE Daikin Industries, Ltd. (JP) 2020-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200203769-A1 ELECTROLYTE FOR LITHIUM ION SECONDARY BATTERY, LITHIUM ION SECONDARY BATTERY, AND MODULE CLIC1, CLIC4, CLCN2 LMNA 2528/4885EGLN1 4343/4885ALKBH5 4411/4885
US-20200274199-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ENERGY DEVICE USING SAME SLC26A3, VDAC3, SLC25A13 LMNA 3230/4885EGLN1 2524/4885ALKBH5 4132/4885
US-11945776-B2 Electrolyte, electrochemical device, lithium ion secondary battery, and module CLCN2, SLC26A3, KCNH3 LMNA 2120/4885EGLN1 3770/4885ALKBH5 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.